3 Dividend Stocks Investors Are Watching As Inflation Pressure Builds

Inflation is heating up again, the Fed is hinting at tighter policy, and yet parts of the market are still quietly throwing off cash. That mix of stubborn price pressures and rising rate expectations can punish stretched stories and reward sturdier balance sheets. This piece looks at three large-cap dividend stocks from our value-focused screener that are closely tied to the latest PPI shock, and it discusses why their reaction could matter for your portfolio decisions now.

The three dividend stocks highlighted below are only a small sample, since the full screen surfaced 47 more U.S. large caps with similar value, income and balance sheet stories that are not covered here.

If you want to move quickly from ideas to a working watchlist, head straight to the U.S. Large-Cap Value & Dividend Stocks screener to identify, filter and analyze your highest conviction picks with the same rule set.

National Health Investors (NHI)

National Health Investors fits the U.S. Large-Cap Value & Dividend Stocks theme through its REIT model geared toward income and senior housing exposure. This tends to appeal when inflation and rates are higher.

National Health Investors is a healthcare REIT that owns, leases, operates and finances senior housing and medical properties across the U.S., generating about US$296 million from Real Estate Investments and US$158 million from its SHOP segment, with a market value near US$3.2b.

The analyst consensus Narrative on Simply Wall St frames National Health Investors as a senior housing landlord whose appeal rests on demographics, capital recycling and a mix of operating and triple net assets that aim to support income-focused investors through inflation and rate swings.

Accelerating growth in the 75+ U.S. population and limited new senior housing construction continue to support occupancy and pricing power for National Health Investors' SHOP portfolio, which can feed into higher revenue and NOI over time.

What really shifts the risk reward balance is how one less visible cost pressure interacts with that demand story and filters through to margins.

That margin wildcard is exactly what the full narrative for National Health Investors unpacks, separating durable income potential from risks that could quietly limit future upside.

FedEx (FDX)

FedEx is the classic U.S. Large-Cap Value & Dividend Stocks candidate, a mature logistics giant that ties together e-commerce, freight and global shipping into one income-focused story.

FedEx runs global parcel, freight and logistics operations, with Federal Express producing about US$82.3b of its revenue and FedEx Freight around US$8.8b, plus smaller Corporate and Other contributions, and the stock valued near US$75.6b.

The analyst consensus Narrative on Simply Wall St frames FedEx as a value leaning dividend payer where cost discipline and pricing decisions now matter more than raw volume growth.

FedEx's DRIVE and Network 2.0 programs continue to reshape the cost base, with billions of dollars already removed and a further US$2b of Network 2.0 savings targeted by the end of 2027, which could support higher net margins and earnings.

What happens if one less visible pressure on FedEx's pricing power shifts at the same time as those cost savings start to flow through?

If that pressure is building in the background, the full narrative for FedEx shows where FedEx could still accelerate, where risks cluster, and what the market may be missing.

Quest Diagnostics (DGX)

Quest Diagnostics gives this screener a pure play on U.S. healthcare demand, pairing a large-cap dividend profile with diagnostic services that people and insurers still rely on even when inflation and rates are climbing. This is exactly how the analyst consensus Narrative on Simply Wall St frames the opportunity.

Quest Diagnostics runs a broad diagnostics and health services platform, generating about US$11.6b from Diagnostic Information Services and US$254 million from DS Revenues, all from U.S. customers, with the stock valued around US$28.5b.

The continuing shift toward preventive healthcare and wellness, supported by Quest Diagnostics’ roughly US$300 million consumer business that is growing at about 30% and is expected by management to grow more than 20% annually over the next 3 to 5 years with margins above the corporate average, is setting up a larger recurring revenue base and higher earnings contribution from cash-pay testing.

What happens to that income story if one unresolved pressure quietly squeezes how much of each new testing dollar actually falls to the bottom line?

That squeeze is exactly what the full narrative for Quest Diagnostics unpacks, revealing where Quest Diagnostics’ cash-pay momentum could accelerate, stall, or quietly mask a stronger earnings profile.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. Breakout stories gain momentum while slow movers get caught holding stocks that are already flying. Scan what is still under the radar for now and act early.

• Spot income workhorses before yields start dropping by running a targeted sweep through our curated 6 dividend fortresses that focuses on durable payouts and solid backing.
• Hunt for resilient operators built to handle shocks by zeroing in on a curated 29 resilient stocks with low risk scores that screens for quality, balance sheet strength and steadier trading profiles.
• Explore the next wave of infrastructure demand by scanning a focused 44 power grid technology and infrastructure stocks that highlights businesses tied to grid upgrades, reliability projects and future capacity needs.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com